Blueprint Medicines (NASDAQ:BPMC) Lifted to “Strong-Buy” at Baird R W
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by stock analysts at Baird R W to a “strong-buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports. BPMC has been the topic of a number of other reports. Barclays upped their price target on Blueprint Medicines from $75.00 to […]
More Stories
World Athletics to Require Genetic Test for Female Competition Eligibility
By Haika Mrema World Athletics announced a new regulation on July 30 that will require athletes to undergo a one-time...
Law Enforcement Search for Shooting Suspect After 4 Killed in Montana
By Michael Clements A mass shooting at the Owl Bar in Anaconda, Montana, on Aug. 1 resulted in multiple fatalities,...
Trump Orders Nuclear Submarines Moved After Former Russian President’s Comments
By Jack Phillips President Donald Trump on Friday announced that he ordered U.S. nuclear submarines to be moved following comments...
Fed Governor Announces Resignation, Giving Trump a Nominee on Interest Rate Setting Committee
By Tom Ozimek The Federal Reserve has announced that Fed Governor Adriana Kugler is resigning early from her term and...
US Factory Employment Drops to 5-Year Low as Manufacturing Slump Deepens
By Tom Ozimek American factory employment sank in July to the lowest level since mid-2020, underscoring a deepening manufacturing downturn...
Can People See Your ChatGPT Chats? Privacy Warning for Users
What if something you shared with an AI tool showed up on Google for anyone else to see? That’s exactly...